Navigation Links
FDA Reviewing Biomoda Submission for Cancer Screening Study
Date:8/4/2008

ALBUQUERQUE, N.M., Aug. 4 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, submitted to the FDA a pre-IDE (Investigational Device Exemption) protocol for a clinical study using Biomoda's proprietary assay for detection of early lung cancer in veterans. The New Mexico state legislature allocated more than $1.6 million over two years towards the study that will screen more than 2000 veterans.

"This is an essential step in study development," said John Cousins, President of Biomoda. "Approval by the FDA of the study design this year allows us to move forward quickly to prove the efficacy of the assay. Approval by the Agency of the results of this study that we expect early next year will provide us the ability to market our assay commercially."

Biomoda's patented technology is designed for early lung cancer screening of large populations at a reasonable cost. The non-invasive test, originally developed at Los Alamos National Laboratory, allows clinicians to identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells in the sputum exposed to the assay glow red under fluorescent light and can be detected under a microscope.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a two-phase study of the state's veterans. The initial phase will screen 225 veterans; a second phase will test more than 2000 veterans for lung cancer using Biomoda's non-invasive patented assay.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15%; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16% of lung cancer cases are diagnosed at this early stage.

For more information contact:

John Cousins

505-821-0875

investor@biomoda.com

Forward Looking Statement

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Small Business Innovation Research Program Awards Grant to Biomoda
2. Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting
3. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
4. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
5. Synbiotics Corporation Announces Human Submission for FluDetect(R)
6. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
7. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
8. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
9. Indevus Announces Submission of New Drug Application
10. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
11. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... based in St. Joseph, Missouri , has selected AccuReg to help ... in 22 cities, and its flagship St. Joseph Medical Center. Mosaic Life ... care to its patients, including the insurance, billing and collections processes. ... ... St. Joseph Medical Center ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure By Technique, ... ... Devices Market is forecasted to grow at a CAGR of 13.35% ... is driven by rising aging population, growth in population with heart ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner ... in Frederick, MD. Judy says, “I am passionate about sharing Reiki as a ... very difficult and challenging time.” , A Certified Medical Reiki™ Master trained by ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization declared the ... four million Zika-related cases in the Americas within the next year. Lyme disease is ... per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
Breaking Medicine News(10 mins):